Knowridge Science Report4d
This drug may slow cognitive decline in dementia with Lewy bodies
Dementia with Lewy bodies (DLB) is a complex condition that shares features with both Alzheimer’s disease and Parkinson’s ...
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
ZUNVEYL (benzgalantamine) is a twice-daily treatment designed to address the cognitive symptoms of mild-to-moderate Alzheimer’s disease. By enhancing cholinergic function in the brain, ZUNVEYL ...
C&EN20d
Synthesis, Pharmacological Evaluation, and Molecular Modeling of Phthalimide Derivatives as Monoamine Oxidase and Cholinesterase Dual Inhibitors
Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan Department of Chemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan ...
C&EN23d
Esterified Indole-3-propionic Acid: A Novel Inhibitor against Cholinesterase Identified through Experimental and Computational Approaches
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.
verywellhealth26d
Current Treatment Options for Alzheimer's Disease
They include cholinesterase inhibitors, N-methyl D-aspartate (NMDA) antagonists, and amyloid beta-directed antibodies. Cholinesterase inhibitors act by preventing the breakdown of acetylcholine in the ...
MedPage Today26d
For Your Patients: Navigating Treatment Options in Early Stage Alzheimer’s Disease
Your doctor may prescribe a type of drug called a cholinesterase inhibitor, most commonly donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne). By blocking breakdown of an ...